Bottom line
JDOC vs RYHIX: the short answer
JDOC (JPMorgan Healthcare Leaders ETF) and RYHIX (Health Care Fund) share a meaningful slice of their top holdings — about 64% by weight.
But RYHIX is far broader, holding 135 positions to 61 for JDOC, so beyond the top names it adds exposure JDOC doesn't have.
JDOC is cheaper at 0.65% vs 1.38% — a difference of $73 a year per $10,000 invested.
Over one year, JDOC returned +14.9% vs +14.4% for RYHIX.
Updated Nov 19, 2026
JDOC vs RYHIX side by side
| JDOC | RYHIX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | J.P. Morgan | Guggenheim |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.65% | 1.38% |
| Annual cost per $10k | $65 | $138 |
| 10-yr cost on $10k (prospectus) | $810 | $1,709 |
| Max front load | None | — |
| 12b-1 fee | — | 0% |
| 1-yr return | +14.9% | +14.4% |
| 5-yr return (annualized) | — | +5.1% |
| 10-yr return (annualized) | — | +7.9% |
| Best quarter | +11.3% | +18.7% |
| Worst quarter | −11.9% | −14.4% |
| Net assets (fund) | $9.1M | $19.4M |
| Number of holdings | 61 | 135 |
| Portfolio turnover | 92% | 244% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | JDOC | RYHIX | Difference |
|---|---|---|---|
| 2025 | +14.9% | +14.4% | +0.5% |
| 2024 | −0.6% | +0.6% | −1.2% |
Source: Fund prospectus bar charts
Holdings overlap
15 of JDOC's top 25 holdings also appear in RYHIX's top 25.
| Holding | JDOC | RYHIX |
|---|---|---|
| AbbVie, Inc. | 7.85% | 2.52% |
| Eli Lilly & Co. | 7.76% | 3.63% |
| UnitedHealth Group, Inc. | 5.85% | 2.22% |
| Merck & Co., Inc. | 4.82% | 2.04% |
| Johnson & Johnson | 4.82% | 2.88% |
| Thermo Fisher Scientific, Inc. | 3.73% | 1.61% |
| Bristol-Myers Squibb Co. | 3.57% | 1.22% |
| Abbott Laboratories | 3.11% | 1.42% |
| CVS Health Corp. | 2.83% | 1.31% |
| Stryker Corp. | 2.23% | 1.21% |
| Danaher Corp. | 2.16% | 1.30% |
| Intuitive Surgical, Inc. | 1.93% | 1.31% |
| Edwards Lifesciences Corp. | 1.73% | 0.84% |
| Regeneron Pharmaceuticals, Inc. | 1.60% | 0.90% |
| Cardinal Health, Inc. | 1.51% | 0.86% |
Source: SEC Form N-PORT
JDOC top 10
- AbbVie, Inc. — 7.85%
- Eli Lilly & Co. — 7.76%
- UnitedHealth Group, Inc. — 5.85%
- Merck & Co., Inc. — 4.82%
- Johnson & Johnson — 4.82%
- AstraZeneca plc — 3.76%
- Thermo Fisher Scientific, Inc. — 3.73%
- Bristol-Myers Squibb Co. — 3.57%
- Abbott Laboratories — 3.11%
- CVS Health Corp. — 2.83%
RYHIX top 10
- Eli Lilly & Company — 3.63%
- Johnson & Johnson — 2.88%
- Abbvie Inc — 2.52%
- Unitedhealth Group Inc — 2.22%
- Merck & Company Inc — 2.04%
- Thermo Fisher Scientific Inc — 1.61%
- Amgen Inc — 1.56%
- Abbott Laboratories — 1.42%
- Gilead Sciences Inc — 1.39%
- Vertex Pharmaceuticals Inc — 1.34%
FAQ
What is the difference between JDOC and RYHIX?
Which is cheaper, JDOC or RYHIX?
Should I own both JDOC and RYHIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.